Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico

BACKGROUND: Warm autoimmune hemolytic anemia (w-AIHA) is an uncommon disease with heterogeneous response to treatment. Steroids are the standard treatment at diagnosis, whereas rituximab has recently been recommended as the second-line therapy of choice. Our main objective was to document the respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaime-Pérez, José Carlos, Aguilar-Calderón, Patrizia, Salazar-Cavazos, Lorena, Gómez-De León, Andrés, Gómez-Almaguer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614091/
https://www.ncbi.nlm.nih.gov/pubmed/31309092
http://dx.doi.org/10.5045/br.2019.54.2.131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614091/
https://www.ncbi.nlm.nih.gov/pubmed/31309092
http://dx.doi.org/10.5045/br.2019.54.2.131

Ejemplares similares